Thursday, October 16, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Ratings and Price Targets for Quest Diagnostics

Elaine Mendonca by Elaine Mendonca
February 2, 2024
in Breaking News
0
Healthcare Services Stock Exchange
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter

As of February 2, 2024, the sentiment surrounding Quest Diagnostics (NYSE: DGX) among analysts is diverse. Over the past quarter, opinions have ranged from bullish to bearish, as indicated by 7 analysts. Let’s take a closer look at their recent ratings and how they compare to previous months:

– Bullish: 1 rating
– Somewhat Bullish: 0 ratings
– Indifferent: 6 ratings
– Somewhat Bearish: 0 ratings
– Bearish: 0 ratings

Within the last 30 days, there have been no bullish ratings, indicating a shift in sentiment. One month ago, there were no changes in ratings. Two months ago, there was one bullish rating, three indifferent ratings, and no bearish ratings. Three months ago, there were no bullish ratings, two indifferent ratings, and no bearish ratings.

The average 12-month price target for Quest Diagnostics is $146.57, with a high estimate of $160.00 and a low estimate of $137.00. This average has increased from the previous average price target of $139.71, suggesting a 4.91% rise.

Recent actions by analysts have involved adjustments to both ratings and price targets. For example, David Macdonald of Truist Securities initially lowered the “Hold” rating from $150.00 to $145.00, but later raised it back to $150.00 from $145.00. Derik De Bruin of B of A Securities raised the “Buy” rating from $140.00 to $160.00, and other analysts have made similar adjustments.

In summary, the analyst ratings for Quest Diagnostics exhibit a range of opinions, with a consensus of “Hold” based on the ratings of 10 Wall Street analysts. The average price target stands at $148.00, with a high forecast of $165.00 and a low forecast of $137.00. This suggests a potential upside of 13.95% from the current price.

Quest Diagnostics (DGX) Stock Performance Disappoints on February 2, 2024: Potential Downtrend and Concerns for Investors

On February 2, 2024, the stock performance of Quest Diagnostics (DGX) was closely monitored by investors and analysts. The data revealed that DGX was trading near the bottom of its 52-week range and was also below its 200-day simple moving average. These indicators hinted at a potential downtrend for the stock.

One of the key factors contributing to this downward trend was the recent price change in DGX shares. The stock had experienced a decrease of $2.17 since the market last closed, representing a 1.71% drop.

Closing at $125.00, DGX had reached a price level that was concerning for investors. The stock’s proximity to its 52-week low suggested that it may be undervalued, but it also raised concerns about the company’s financial performance and market sentiment.

To gain further insights, investors also observed the after-hours trading activity for DGX on February 2, 2024. Surprisingly, the stock remained unchanged during this period. While this stability could be seen as a positive sign, it also indicated that there was no immediate rebound in sight for DGX.

Overall, the stock performance of DGX on February 2, 2024, was disappointing, with the stock trading near its 52-week low and below its 200-day simple moving average. The decline of $2.17, equivalent to a 1.71% drop, had a negative impact on investor sentiment. The closing price of $125.00 and the lack of movement in after-hours trading further highlighted the challenges faced by DGX.

Investors and analysts will continue to closely monitor DGX’s performance in the coming days. The stock’s ability to rebound from its current position and regain momentum will be crucial for its future prospects.

DGX Stock Performance on February 2, 2024: Declines in Total Revenue, Net Income, and EPS Raise Concerns for Investors

DGX Stock Performance on February 2, 2024:

– Total revenue: $9.25 billion, a 6.38% decrease compared to the previous year. Revenue has remained flat since the last quarter.
– Net income: $850 million, a 9.77% decrease compared to the previous year. Net income declined by 13.9% since the last quarter.
– Earnings per share (EPS): $7.52, a 5.77% decrease compared to the previous year. EPS remained unchanged since the last quarter.

These declines in total revenue, net income, and EPS may be attributed to factors such as changes in market demand, competition, or internal operational challenges. Investors should closely monitor DGX’s financial performance and consider broader economic and industry-specific factors before making investment decisions.

Tags: DGX
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Alternative Energy Markets and money (1)

CN Energy Group Inc Secures Continued Listing on Nasdaq

COST stock news

Mark Zuckerbergs Meteoric Rise The Power of Tech and Wealth

Industrial Metals and Mining Stock Exchange

United States Lime Minerals Announces 25 Increase in Quarterly Dividend

Recommended

Groundbreaking Research Reveals Promising Treatment for OxaliplatinInduced Peripheral Neuropathy

2 years ago
MMP stock news

ETF Managers Group LLC’s New Investment in Ultragenyx Pharmaceutical Inc.: A Turning Point for the Biopharmaceutical Company’s Future

2 years ago
S&P 500 Stock

S&P 500 Futures Signal Cautious Open Following Holiday Weekend

1 month ago
GD stock news

Scotiabank Analyst Reiterates Positive Outlook on Sociedad Quimica Y Minera with Revised Price Target

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Beyond Meat Shares Plummet as Debt Deal Triggers Massive Dilution

S&P 500 Seeks Firmer Footing After Volatile Session

Philip Morris Bets Billions on Smoke-Free Transition Strategy

T-Mobile US: Conflicting Signals Create Investor Dilemma

Pharmaceutical Giant AbbVie Faces Critical Test Amid Acquisition and Patent Challenges

Is Exxon Mobil Stock Poised for a Breakout?

Trending

Viking Therapeutics Stock
Earnings

Viking Therapeutics Stock Faces Critical Test as Earnings Approach

by Robert Sasse
October 16, 2025
0

Shares of Viking Therapeutics are experiencing significant price swings as investors position themselves ahead of the company's...

Trade Desk Stock

The Trade Desk Faces Critical Test Amid Analyst Downgrade

October 16, 2025
Procter & Gamble Stock

Procter & Gamble Shares Slide to Annual Low Despite Dividend Increase and Strong Shareholder Support

October 16, 2025
Beyond Meat Stock

Beyond Meat Shares Plummet as Debt Deal Triggers Massive Dilution

October 16, 2025
S&P 500 Stock

S&P 500 Seeks Firmer Footing After Volatile Session

October 16, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Viking Therapeutics Stock Faces Critical Test as Earnings Approach
  • The Trade Desk Faces Critical Test Amid Analyst Downgrade
  • Procter & Gamble Shares Slide to Annual Low Despite Dividend Increase and Strong Shareholder Support

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com